ArticlePloS one2026
Temporal dynamics of prognostic factors in breast cancer survival.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to explore how relevant factors could have shifting prognostic impacts on mortality among BC patients over time, applying alternative survival model specifications.
methodsGiven data from the Cancer Registry of Norway we followed 36 412 women aged 40 + , breast cancer (BC) diagnosed 2006-2020. We analyzed survival comparing patient's molecular subtype group and BMI, adjusting for age, tumor stage and treatment, considering incidence rates for BC specific death (BCSD) and other causes of death (OCOD). We explored cause-specific survival models with and without time invariant coefficients.
resultsAltogether 8.6% (2 542 patients) and 7.0% (3 125 patients) died from other causes and BC throughout the study period, respectively.Molecular subtype HR + /HER2-patients had similar BCSD and OCOD incidence rates. For the other patients the BCSD incidence was higher than the OCOD incidence, especially for HR-/HER2+ and HR-/HER2- patients. Allowing for the association between time to BCSD and molecular subtype groups and radiation therapy to vary over time we found that HR-/HER2+ and HR-/HER2- patients had hazard ratios of 3.38 and 3.53 compared to HR + /HER2- patients within 3 years following BC diagnosis, and hazard ratios of respectively 0.93 and 1.62 in the subsequent years. The positive effect of radiation therapy on BCSD was highest in the first years following diagnosis and still positive, albeit much smaller, in the later years. We found no difference in BC mortality risk between underweight, normal weight, overweight and obese patients.
conclusionsOur findings contribute to understanding long-term BC survival. Cause-specific Cox models that assume proportional hazards do not allow for time-varying coefficients. This may lead to overlooked time-varying effects of relevant prognostic factors. Especially with longer time horizons one might draw incorrect conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.